David Spigel, MD
Specialities
- Lung cancer
- Early-phase drug development
- Clinical research
Education
Medical Degree: University of Tennessee
Residency: Indiana University Medical Center
Fellowship: Dana-Farber Cancer Institute
Location
335 24th Avenue North, Suite 200 Â
Nashville, Tennessee 37203Â
Phone: 615-329-7640Â
Fax: 615-234-7723Â
Language
English
Biography
Dr. Spigel is a board-certified medical oncologist at SCRI Oncology Partners. After receiving his medical degree from the University of Tennessee in 1996, he completed an internal medicine residency at Indiana University Medical Center, where he served as chief resident. He went on to pursue oncology and hematology during a fellowship at the Dana-Farber Cancer Institute. In addition to seeing patients, he also serves as the chief scientific officer at SCRI, overseeing all scientific aspects of SCRI’s clinical trial program.
Philosophy
Dr. Spigel is dedicated to providing each patient with the latest advancements in cancer treatment. He works closely with a multidisciplinary team of experts to design individualized treatment plans best suited to each patient’s needs.
Relevant Research
Cancer Discovery
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Lancet Oncology
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
Targeted Oncology
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors